Federal Circuit: No Rehearing After Inhaler Patent Delisting Affirmation

( March 5, 2025, 2:15 PM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals rejected a rehearing petition from Teva Branded Pharmaceutical Products R&D Inc. and related entities, leaving in place a panel’s December opinion affirming a New Jersey federal judge’s order granting delisting counterclaims in a patent dispute stemming from a new drug application (NDA) for ProAir HFA (albuterol sulfate) Inhalation Aerosol....